For Multiple Myeloma Patients, Convenience Now an Important Factor in the Treatment Equation

December 20, 2022

The Covid-19 pandemic revealed the advantages of treatment that involved fewer in-person office visits, according to research presented at American Society of Hematology meeting earlier this month. Researchers also saw a notable increase in the use of Darzalex (daratumumab).

Bispecific Antibody Treatments for Multiple Myeloma Are on Their Way

November 15, 2022

Johnson & Johnson’s Tecvayli (teclistamab-cqyv) has been approved by the FDA, and Pfizer’s elranatamab received breakthrough status that should speed its approval. Bispecific antibodies may be a bridge to CAR-T treatments or an alternative to them.

Young Adult Black Patients With Acute Myeloid Leukemia Patients Have Higher Death Rate

November 15, 2022

The younger Black patients with acute myeloid leukemia (AML) had “alarmingly high” early death rates within the first 30 days of study enrollment, indicating possible delays in diagnosis and care, according to research results reported in the journal Blood Advances.

Move Over, CAR-T. There’s Now a Bispecific Antibody Approved as a Late-Line Treatment for Multiple Myeloma.

October 26, 2022

The FDA approved Tecvayli (teclistamab) yesterday after approving two CAR-T therapies as late-line treatments for multiple myeloma earlier this year. Because it is ‘off the shelf,’ Tecvayli may have advantages over the CAR-T therapies, which are custom made for each patient and involve harvesting the patient's T cells.

Hodgkin Lymphoma Patients Have Higher Cardiovascular Mortality Risk Than Cancer

August 15, 2022

For almost all the patients with stage I or stage II disease, the cumulative incidence of CVD mortality exceeded that of classical Hodgkin lymphoma and other cancers, according to research results published in the journal Cancer.